Invitae Corp (NVTAQ)

[FORDGT]

[In August, 2022 the (NVTA) Invitae Corporation SqueezeTrigger Price was $2.20. If you had purchased NVTA, the trade would have gained 60.84% as of today's price of $3.54. If you had traded 10,000 shares, you would currently have a gain of $13,390.00. /i]
52-Wk Range
1.83 - 32.93

[Brokemillwright]

Gotta say, my level is doing just fine. Clealry you follow ark managment, bet your bag holding amc/gme too

[Porterhouse10]

Yeah considering you level of trading experience that statement is way over your head, "still dont know how to chart yet" hahaaaaaaa, Jayzus Chroist lady

[Brokemillwright]

You were saying??????

[Brokemillwright]

Durr...... how these charts treat ya?????

[Brokemillwright]

Still a bagholder here? Muawhahahaha

[Brokemillwright]

Got stopped out of half

[Brokemillwright]

I learned that lesson last year on another ticker and still dealing with the outcome. Speaking of that I need to set a trailing stop loss now.

[Porterhouse10]

Thanks for that, Sincerely! Smoking White Buffalo in Ft. Lauderdale! I'm down on this, normally would set a Stop Loss, but didnt!

[Brokemillwright]

In revenue, still -408 mil net income, which is better than the previous year of -600 mil with almost half as much revenue. Dunno how to value these spec plays as eps is in the toilet as well so only playing with pocket change

[Brokemillwright]

In revenue, -408m

[Porterhouse10]

They brought in 485 mill last year, their collection of Data is worth a Ton, easy acquisition candidate jmo

[Brokemillwright]

I snagged a little of the 10 below. Newsletter recommended this a while ago with a ridiculous buy up to price but only buy wjat you could lose. Figure it's worth a small gamble now lol

[Porterhouse10]

And Below!

[Porterhouse10]

There it is $10

[Porterhouse10]

Straight to $10 and below, do not pass Go, do not collect $200

[Porterhouse10]

Dilution, not profitable, spend almost as much on R @D as they bring in, competition as will, I'm taking the chance in this range, could be acquired.

[moneymaker290]

What is the driver of this down action??

[Porterhouse10]

Looks like $10 next stop

[Porterhouse10]

Added, adding

[Porterhouse10]

Adding again here soon

[Porterhouse10]

Added $21.46

[Porterhouse10]

Woah!

[jerseyboy]

It was time early this week for me. This stock is beginning to perform as I thought it would.

[Porterhouse10]

Hmmmm, time to add again?

[JJ8]

Which ticker is the one? Me Curious and interested to know.

Cheers.

[Brokemillwright]

I see you on another ticker I'm in. How are you feeling about this one still? It's down 40% since the newsletter I get reccomneded it in 2020 but I haven't found the article, just portfolio update. Going to see if I can dona little digging on this

[Porterhouse10]

Yep these Innovative Genomics have taken a beating, but this is the Future, rotation of funds will be back, these prices are pretty damn inviting and interesting

[jerseyboy]

I did yesterday and the day before, and wish that I had waited until today! Below $30 just seems like an insanely low share price for this company.

[Porterhouse10]

Time to add

[Porterhouse10]

Will be adding here soon! $28 if she wants

[jerseyboy]

This is still a great buying opportunity at this level. I'm planning to hold this for five years and never even consider selling.

[jerseyboy]

I never took the position I referred to in my prior post because I used the money for another stock, and now I'm glad I didn't, because this has fallen by a third from its recent public offering price. I got in at just over $34.00 this morning, and I look at it as a tremendous gift from the market. This is similar at this point to where Facebook or Netflix was when they started, in that they see a future of which very few others can conceive. I'm not technically presumptuous enough to say that I understand that future, but I can see that they do, and that should be enough to make me a lot of money by owning part of this company.

[BuyLow_Sell_High]

$400M offering today AH when they have $400M cash already on the balance sheet is making me think they're looking to buy a company. Does anyone have any DD on what that target company might be?

[JJ8]

jerseyboy, Congrats.

You're learning important lessons from your experiences. That's great. The Stock market is quite a challenge and there is just too much too learn. Accepting to learn and make changes in your own shortcomings are equally important in this challenge.

From my own experience of many decades, I still am a bit greedy and that used to be a serious obstacle, and impatience at times caused me big losses... AMZN being hurtful. Still have some traces of both short comings, lol.

The problem is that the same lesson learned in one area is not always of positive and applicable also.

All I can say is that learning using stocks and in my case casino gambling (only Casino BJ), I have personally improved and aware to manage my own feelings and emotions to improve myself. I attitude over time changed and knowledge and understanding improved. And, Attitude is more important than Aptitude and a playful and happy attitude with better money handling and management I became a better "player" who now in retirement I enjoy much more. Having been a Project Manager/Engineer has helped me and I am having better fun now than when I was immature and responding poorly to losses.

fyi, now I hold TSLA shares since November 2020 that has increased in value more than 90%. Since it's potential appears to be good, I am holding will be holding cautiously long term. You have great opportunities in Biotech and in EV stocks, at this time. The larger market is as always tough to predict because it can and will affect all stocks if we get into a deep recession.

Take care and GLTY

[jerseyboy]

I have finally come to understand that the secret to making money in investing is not in understanding the present, but in seeing the future. I couldn't see the future in Facebook and Netflix when they were cheap, and paid the price for my shortsightedness. I will not repeat that mistake again, because that would indicate that I am stupid rather than ignorant, and I am far from stupid. I am taking a strong position here on Monday morning.

[moneymaker290]

63 a share last week...WHAT HAPPENED??

[Timetravelerdos]

Really good information presented this past week. Read the full article: Invitae to Present New Data Supporting Genetic Testing for All Breast Cancer Patients at the 2020 San Antonio Breast Cancer Symposium.

Plus NVTA is the #1 holding in the ARKG portfolio and has a 251% YTD return. The current $56 share price is not scaring people away. I understand taking profits but Invitae is staying in my portfolio.

https://finance.yahoo.com/news/invitae-present-data-supporting-genetic-123000993.html

[Timetravelerdos]

Invitae to Present New Data Supporting Genetic Testing for All Breast Cancer Patients at the 2020 San Antonio Breast Cancer Symposium
PR Newswire
7:30 AM ET
Invitae (NYSE: NVTA), a leading medical genetics company, today announced three studies demonstrating the benefits of genetic testing for all breast cancer patients, impacting treatment decisions and cancer screening for patients and their families. The studies, which will be presented at the 2020 San Antonio Breast Cancer Symposium (SABCS), add to the evidence supporting universal access to genetic information for all breast cancer patients.

https://mma.prnewswire.com/media/268592/invitae_corporation_logo.jpg

"It's clear that current guidelines are too restrictive and, as a result, many patients with breast cancer whose care could be improved by access to precision medicine approaches are being missed. Universal testing for all patients with solid tumor cancer, including breast cancer, can help inform treatment and improve outcomes for patients," said Robert Nussbaum, M.D., chief medical officer of Invitae. "These data, taken together with many other studies that demonstrate the utility of universal testing for cancer patients, show the time has come to expand testing guidelines to ensure all breast cancer patients and their families can benefit from incorporating genetic information into their care."

In a prospective, multi-center study of breast cancer patients, one in eight patients had inherited genetic variants that could increase their risk of more aggressive disease and inform treatment choices. Despite the patients having inherited genetic variants, testing rates among patients' families remained low, even when cost was not a barrier. These findings in breast cancer patients were part of a landmark study across various solid tumor cancers recently published in JAMA Oncology.

Findings of a second study at the meeting underscore the impact germline testing can have on patient outcomes. In the longitudinal study, researchers evaluated the clinical outcomes of breast cancer patients who had undergone testing as part of a registry that included patients who met testing criteria and those who did not. Notably, 60% of patients who received targeted chemotherapy based on germline variants were in the group that did not meet testing criteria, highlighting the possibil ity that certain beneficial treatments and management changes could be inappropriately withheld from patients if restrictive criteria persist.

The third study at the meeting examined select international germline genetic testing criteria from Canada, Australia and the United Kingdom, and its impact on limiting access to testing in patients and their families who may benefit from this information. The study applied the international testing criteria to a cohort of previously tested U.S. breast cancer patients and found that more than 70% of patients with pathogenic variants would have been excluded using current guidelines to allocate germline testing. Furthermore, >80% of the pathogenic variants detected in these out-of-criteria patients were in genes with published management guidelines. Thi s study demonstrates that current international guidelines for genetic testing are overly restrictive and miss actionable findings that could benefit breast cancer patients and their families.

[Pennybuster]

i added a few today on the upgrade.

[Porterhouse10]

Buddy alerted me to this, same friend alerted $FSLY at $29, stated a position today, and will build around it jmo

[lhughbees]

Science is well established here.

[Golden Cross]

NVTA 50/200sma crossed bullish on the chart Friday.

[ClayTrader]

* * $NVTA Video Chart 06-22-2020 * *

Link to Video - click here to watch the technical chart video

[Gpheart2016]

NVTA up 15% today after Motley Fool recommendation. Shorts are holding 20% of shares so this surge could last a couple of days as the squeeze gains momentum.

[whytestocks]

News: $NVTA Invitae Announces Program with BioMarin to Expand Access to Genetic Testing for Skeletal Dysplasias

SAN FRANCISCO , Dec. 10, 2019 /PRNewswire/ --  Invitae (NYSE: NVTA), a leading medical genetics company, today announced the launch of Discover Dysplasias™ , an initiative with BioMarin Pharmaceutical to offer genetic testing at no charge to patients who show signs or symp...

Got this from NVTA - Invitae Announces Program with BioMarin to Expand Access to Genetic Testing for Skeletal Dysplasias

[whytestocks]

News: $NVTA Invitae Launches Invitae Discover Research Platform on Apple Watch; First Study on Platform Will Investigate Genetic Causes of Cardiovascular Disease

PHILADELPHIA , Nov. 15, 2019 /PRNewswire/ --  Invitae Corporation (NYSE: NVTA), a leading medical genetics company, today announced Invitae Discover , a clinical research platform that leverages biometric data available through Apple Watch to provide better understanding of the...

Got this from NVTA - Invitae Launches Invitae Discover Research Platform on Apple Watch; First Study on Platform Will Investigate Genetic Causes of Cardiovascular Disease

[half-full]

Looks like that article was on point. Thanks. Good day.

[whytestocks]

$NVTA bears and bulls Invitae Corporation Nyse Nvta Short Squeeze

[whytestocks]

News: $NVTA Invitae to Acquire Clear Genetics

SAN FRANCISCO , Nov. 11, 2019 /PRNewswire/ --  Invitae Corporation  (NYSE: NVTA), a leading medical genetics company, today announced it has entered into a definitive agreement to acquire Clear Genetics, a leading developer of software for providing genetic services at scale. Us...

In case you are interested NVTA - Invitae to Acquire Clear Genetics